Abstract
AbstractBackgroundAtrial cardiomyopathy is known as an underlying pathophysiological factor in the majority of AF patients. Left atrial low-voltage areas (LVAs) are reported to coincide with fibrosis, and to likely represent atrial cardiomyopathy. This study aimed to delineate differences in the long-term prognosis of patients stratified by the size of LVAs.MethodsThis observational study included 1,488 consecutive patients undergoing initial ablation for AF. LVAs were defined as regions with a bipolar peak-to-peak voltage of < 0.50 mV. The total study population was divided into 3 groups stratified by LVA size: patients with no LVAs (n=1136), those with small (< 20 cm2, n=250) LVAs, and those with extensive (≥ 20 cm2, n=102) LVAs. Composite endpoints of death, heart failure, and stroke were followed for up to 5 years.ResultsComposite endpoints developed in 105 (7.1%) of 1488 patients, and AF recurrence occurred in 410 (27.6%). Composite endpoints developed more frequently in the order of patients with extensive LVAs (19.1%), small LVAs (10.8%), and no LVAs (5.1%; p for trend<0.0001). Multivariable analysis revealed that LVA presence was independently associated with higher incidence of composite endpoints, irrespective of AF recurrence (modified hazard ratio=1.73, 95% confidence interval=1.13-2.64, p=0.011)ConclusionsLVA presence and its extent were both associated with poor long-term composite endpoints of death, heart failure, and stroke, irrespective of AF recurrence or other confounders. Underlying atrial cardiomyopathy appears to define a poor prognosis after AF ablation.Clinical perspectiveWhat is KnownPatients with left atrial low-voltage area has high incidence of atrial fibrillation recurrence after ablationWhat the study addsPresence of low-voltage areas was associated with poor prognosis including death, heart failure hospitalization, and stroke.Graphic abstract
Publisher
Cold Spring Harbor Laboratory
Reference30 articles.
1. ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC;ESC Scientific Document Group;Eur Heart J,2020
2. Atrial Cardiomyopathy
3. High Prevalence of Occult Heart Failure With Preserved Ejection Fraction Among Patients With Atrial Fibrillation and Dyspnea
4. Atrial Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation
5. Yamaguchi T , Otsubo T , Takahashi Y , Nakashima K , Fukui A , Hirota K , Ishii Y , Shinzato K , Osako R , Tahara M , Kawano Y , Kawaguchi A , Aishima S , Takahashi N , Node K . Atrial structural remodeling in patients with atrial fibrillation is a diffuse fibrotic process: evidence from high-density voltage mapping and atrial biopsy. J Am Heart Assoc 2022; 11:e024521.